Dechra Pharma Takes EQT Takeover Offer, Albeit At Lower Price
Portfolio Pulse from Lekha Gupta
Dechra Pharmaceuticals has agreed to a £4.5 billion takeover offer by EQT at a 44% premium to its closing price on April 12, 2023. The acquisition is expected to complete by the end of 2023 or early 2024. Dechra now expects full-year underlying operating profit to be materially below the guidance of £186 million.
June 02, 2023 | 11:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dechra Pharmaceuticals agrees to a £4.5 billion takeover offer by EQT, with the acquisition expected to complete by the end of 2023 or early 2024.
The acquisition by EQT is expected to have a positive short-term impact on Dechra Pharmaceuticals' stock price, as the offer represents a 44% premium to its closing price on April 12, 2023. The deal is expected to complete by the end of 2023 or early 2024, providing certainty for shareholders.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Dechra Pharmaceuticals agrees to a £4.5 billion takeover offer by EQT, with the acquisition expected to complete by the end of 2023 or early 2024.
The acquisition by EQT is expected to have a positive short-term impact on Dechra Pharmaceuticals' stock price, as the offer represents a 44% premium to its closing price on April 12, 2023. The deal is expected to complete by the end of 2023 or early 2024, providing certainty for shareholders.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100